To solve this critical challenge, he founded Nephrogen in 2022, a biotech startup that uses AI and advanced screening to ...
Chromatin Bioscience is pleased to announce an ongoing research collaboration with Purespring Therapeutics, a precision nephrology company leading the development of targeted, first-in-class genetic ...
Intellia Therapeutics said it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was ...
Scientists at The University of Texas at Austin have developed a revolutionary gene-editing method using bacterial retrons ...
GSK's London-listed shares fell about 2% on Friday after the U.S. Food and Drug Administration approved only one of two ...
Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...
The approach, published on 23 October in Science, builds on a trend that is sweeping the field of drug discovery: the use of ...
Because the new method can replace a large stretch of defective DNA with a healthy sequence, the same retron-based package can fix any combination of mutations within that stretch of DNA without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback